AMI Asset Management Corp Purchases 10,849 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

AMI Asset Management Corp increased its position in SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) by 27.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,640 shares of the company's stock after acquiring an additional 10,849 shares during the quarter. AMI Asset Management Corp owned about 0.07% of SpringWorks Therapeutics worth $2,235,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers lifted its position in SpringWorks Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 101,904 shares of the company's stock valued at $3,682,000 after purchasing an additional 2,251 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in SpringWorks Therapeutics during the fourth quarter valued at approximately $45,000. Los Angeles Capital Management LLC lifted its position in SpringWorks Therapeutics by 30.8% during the fourth quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company's stock valued at $2,231,000 after purchasing an additional 14,548 shares during the last quarter. Mutual of America Capital Management LLC lifted its position in SpringWorks Therapeutics by 1.6% during the fourth quarter. Mutual of America Capital Management LLC now owns 116,932 shares of the company's stock valued at $4,225,000 after purchasing an additional 1,898 shares during the last quarter. Finally, US Bancorp DE lifted its position in SpringWorks Therapeutics by 56.0% during the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock valued at $157,000 after purchasing an additional 1,556 shares during the last quarter.

SpringWorks Therapeutics Stock Up 0.0%

NASDAQ:SWTX opened at $46.97 on Thursday. The company has a fifty day moving average of $45.69 and a 200 day moving average of $44.08. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $62.00. The firm has a market capitalization of $3.54 billion, a P/E ratio of -13.77 and a beta of 0.70.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The firm had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. SpringWorks Therapeutics had a negative net margin of 115.60% and a negative return on equity of 51.10%. As a group, analysts anticipate that SpringWorks Therapeutics will post -2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SWTX. Guggenheim reiterated a "neutral" rating and set a $47.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. TD Cowen restated a "hold" rating and issued a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Evercore ISI lowered shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Cowen lowered shares of SpringWorks Therapeutics to a "hold" rating in a report on Tuesday, April 29th. Finally, Barclays restated an "equal weight" rating and issued a $47.00 price objective (down from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of "Hold" and an average target price of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics (NASDAQ:SWTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.